Connective Tissue Disease: Increasing Research and Development Expenditure will Boost The Market Growth at a Strong CAGR of ~ 11.5% During The Forecast Period 2022-2030

Pune, India, December, 2022/MRFR Press Release/- Market Research Future has a half cooked research report on the connective tissue disease market.

Market Highlights

Connective tissue disease is a group of medical diseases. Various connective tissue disorders feature abnormal immune system activity along with inflammation in tissues. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels.

According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway and Poland.

Rising prevalence of connective tissue disease, high unmet needs of current treatment, and increase in research and development expenditure will promote the growth of connective tissue disease market.

Lack of infrastructure in the middle and low income countries may hamper the growth of the market.

The Connective Tissue Disease Market is expected to reach USD 3,851.14 Million by 2030 at11.5% CAGR during the forecast period 2022 -2030.

Regional Analysis

The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), it is found that out of total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.

Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.

Asia Pacific is the fastest growing connective tissue disease market owing to the huge patient pool, developing healthcare technology, and rising healthcare expenditure in some region. According to the Australian Institute of Health and Welfare, in the years 2015 and 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.

The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities.

Segmentation

The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, market is segmented into physical examination, X-ray Examination, ANA (Antinuclear Antibody Test), and others.

On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others

On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.

Key Players

Some of key the players in the market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, Pfizer, AutoImmune Inc., Johnson & Johnson, Amgen Inc., AstraZeneca, Eli Lilly and Company, Biogen, LUPIN, and others.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of  Connective Tissue Disease Market Research Report